research use only
Cat.No.E0878
Chemical Structure
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | Formula | Storage (From the date of receipt) | |||
|---|---|---|---|---|---|
| CAS No. | 1303420-67-8 | -- | Storage of Stock Solutions | Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt. | |
| In vivo |
The survival of microglia depends on the CSF1R signaling pathway. Clearing microglia at different times and spaces (before, during, or after injury or disease) will have different impacts on the development, homeostasis, and diseases of the central nervous system. Therefore, the pharmacological manipulation of microglia using CSF1Ri (CSF1R inhibitor) can provide insights into brain functions.
In many peer-reviewed publications, PLX5622 is most commonly administered via ad libitum feeding. Consequently, the validation studies of PLX5622 performed by Selleck were conducted by providing mice with AIN-76A diets supplemented with PLX5622.
The PLX5622-supplemented AIN-76A diet (1200 ppm) provided by Selleck is blue in color. Concurrently, Selleck supplies an equivalent quantity of PLX5622-free AIN-76A diet (no added pigments) as a complementary provision, which serves as the control group diet.
Precautions for the Use of PLX5622 in AIN-76A Diet (1200 ppm)
1.Sampling on the day when the experiment ends:
The literature (Cell. 2020 Mar 5;180(5):833-846.e16.) indicate that there are significant differences in the detected IBA1+ signals when sampling is done 6 hours later and 3 days later.
2.Optimal usage period:
It is recommended to use up the feed within half a year when stored at -20°C (to ensure the palatability of the feed). It is advisable to reduce repeated freezing and thawing. The diet required during the experiment can be stored at 4°C and should be used up during the experiment.
Store the diet away from light. After each feeding of the mice, make every effort to expel as much air as possible from the feed bag and seal it tightly.
3.Calculate the feed consumption:
For mice weighing 20-25 g, the daily feed consumption is approximately 4 g. It is recommended to calculate the feed consumption of the mice and replace and add the feed every 1-2 days. Do Not provide a large amount of feed to the mice at one time without replacing it during the experiment.
4.Concerning self-prepared feed consumption: During the feed synthesis process, approximately 10% loss of both the feed base material and the drug may occur.
Other questions about PLX5622 Diet
Q1: Does γ-ray irradiation affect the product’s bioactivity?
A1: The primary objective of γ-ray irradiation is to ensure the feed’s suitability for use in Specific Pathogen Free (SPF)-level animal barrier facilities. Under a reasonable irradiation dose, it does not impact the activity of small-molecule compounds. However, γ-ray irradiation may disrupt fat chains, alter the feed’s original odor, reduce palatability, and cause partial loss of amino acids and vitamins in the nutritional components. Prompt use of the feed is recommended.
Q2: Can I prepare the custom diet myself?
A2: The critical aspect of feed preparation is the uniformity of drug distribution during the feed-stirring process. Selleck ensures batch-to-batch homogeneity of the feed and guarantees that PLX5622 is uniformly mixed in the AIN-76A diet.
Q3: How should the diet be changed?
A3: As custom diets typically have slightly lower palatability than conventional diets, improper diet transition may result in animal anorexia and reduced feed intake. A diet transition via pre-feeding fasting is recommended. Specifically, experimental animals should be fasted for 24 hours before the custom diet is introduced.
Selleck has not independently confirmed the accuracy of these methods. They are for reference only.
|
|---|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.